Jimenez Jimenez, Antonio M De Lima, Marcos Komanduri, Krishna V Wang, Trent P Zhang, Mei-Jie Chen, Karen Abdel-Azim, Hisham Abid, Muhammad Bilal Aljurf, Mahmoud Alkhateeb, Hassan
...
Cytogenetic and molecular abnormalities are known to influence post-transplant outcomes in acute myeloid leukemia (AML) but data assessing the prognostic value of combined genetic models in the HCT setting are limited. We developed an adapted European LeukemiaNet (aELN) risk classification based on available genetic data reported to the Center for ...
Kantarjian, Hagop M Begna, Kebede H Altman, Jessica K Goldberg, Stuart L Sekeres, Mikkael A Strickland, Stephen A Arellano, Martha L Claxton, David F Baer, Maria R Gautier, Marc
...
BackgroundAcute myeloid leukemia (AML) is fatal in elderly patients who are unfit for standard induction chemotherapy. The objective of this study was to evaluate the survival benefit of administering sapacitabine, an oral nucleoside analogue, in alternating cycles with decitabine, a low-intensity therapy, to elderly patients with newly diagnosed A...
Marx, Christian Sonnemann, Jürgen Beyer, Mandy Maddocks, Oliver DK Lilla, Sergio Hauzenberger, Irene Piée‐Staffa, Andrea Siniuk, Kanstantsin Nunna, Suneetha Marx‐Blümel, Lisa
...
Late-stage colorectal cancer (CRC) is still a clinically challenging problem. The activity of the tumor suppressor p53 is regulated via post-translational modifications (PTMs). While the relevance of p53 C-terminal acetylation for transcriptional regulation is well defined, it is unknown whether this PTM controls mitochondrially mediated apoptosis ...
Liao, Yu-Mei Wang, Ya-Hui Hung, Jung-Tung Lin, Yu-Ju Huang, Yen-Lin Liao, Guo-Shiou Hsu, Ya-Ling Wu, Jen-Chien Yu, Alice L
BackgroundExistence of breast cancer stem cells (BCSCs) is implicated in disease relapse, metastasis, and resistance of treatment. β1,3-Galactosyltransferase 5 (B3GALT5) has been shown to be a pro-survival marker for BCSCs. However, little is known about the prognostic significance of B3GALT5 in breast cancer.MethodsPaired tissues (tumor part and a...
Donovan, Elizabeth Martin, Sarah R Seidman, Laura C Zeltzer, Lonnie K Cousineau, Tara M Payne, Laura A Knoll, Marla Weiman, Margorie Federman, Noah C
Purpose: The aims of the current study were to better understand, from the perspective of adolescents and young adults (AYAs) with sarcoma, parents, and providers, the friendship support needs of AYAs with bone and soft tissue sarcoma and the role of social media in facilitating social support for AYAs with sarcoma. Methods: Semistructured intervie...
Konecny, GE Hendrickson, AE Wahner Davidson, TM Winterhoff, BJ Ma, S Mahner, S Sehouli, J Fasching, PA Feisel-Schwickardi, G Poelcher, M
...
PurposeInsulin-like growth factor (IGF) signaling is implicated in pathogenesis and chemotherapy resistance of epithelial ovarian cancer (EOC). We explored efficacy and safety of adding ganitumab, a monoclonal antibody targeting IGF-1R, to carboplatin/paclitaxel (CP) chemotherapy in patients with primary EOC.DesignPatients were randomly assigned to...
Sauder, Candice AM Li, Qian Bold, Richard J Ruddy, Kathryn J Keegan, Theresa HM
BackgroundSecondary cancers account for 16% of all new cancer diagnoses, with breast cancer (BC) the most common secondary cancer. We have shown that secondary BC has unique characteristics and decreased survival compared with primary BC in adolescent and young adults (AYA; 15-39 years old). However, older BC populations are less well studied.Metho...
Jenei, Kristina Raymakers, Adam Meyers, Daniel E Prasad, Vinay
IntroductionWomen continue to be underrepresented in oncology clinical trials, leading to poor, underpowered subgroup analyses that cannot be generalized to cancer patients in practice. In 2014, the US Food and Drug Administration (FDA) released an Action Plan, which included actions to improve the quality and reporting of demographic subgroup data...
Lythgoe, Mark P Prasad, Vinay
Zhang, Shannon Brazel, Danielle Kumar, Priyanka Schafer, Liudmila N Eidenschink, Benjamin Senthil, Maheswari Dayyani, Farshid
BackgroundGastrointestinal (GI) malignancies represent a heterogeneous group of diseases. Traditional tumor markers, though part of standard-of-care, lack sensitivity and specificity. Tumor-informed circulating tumor DNA (ctDNA) assay-based molecular residual disease assessment as well as recurrence and treatment response monitoring can serve as a ...